262 results about "Elastase" patented technology

A method is described for generating blended nucleic acid ligands containing non-nucleic acid functional units. Specifically, a SELEX identified RNA ligand to the integrin gpIIbIIIa is conjugated to the peptide Gly-Arg-Gly-Asp-Thr-Pro (SEQ ID NO:1). This blended RNA ligand inhibits the biological activity of gpIIbIIIa with high specificity. Also described is a single-stranded DNA ligand to elastase coupled to N-methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl (SEQ ID NO:3) ketone. This elastase blended nucleic acid ligand inhibits the biological activity of elastase.

Disclosed are enzyme-activated anti-tumor and anti-metastatic prodrug compounds. The specific enzymes are collagenase(IV) and elastase. Also disclosed are methods of making and using such compounds.

The present invention concerns a composition for retarding skin aging which contains an edible herb medicine or medicines round in Taiwan, in particular a plant extract or extracts having melanine formation-unhibiting, elastase-inhibiting, hyaluronidase-inhibiting, active oxygen-eliminating and / or radical-capturing type antioxidant activities, and a medicinally acceptable base and / or additives for external dermal application. The composition is useful in promoting skin whitening effects, maintaining the tension and elasticity of the skin, facilitating skin moistening and providing the skin with anti-inflammatory and / or anti-allergic properties.

A method for preparing a scaffold material for use in the prosthesis therapy is disclosed. The method comprises (a) lyophilizing a segment of native soft tissue of mammalian origin, heating the lyophilized tissue at a temperature of 100-200° C., and incubating the tissue with elastase to selectively remove elastin leaving the extracellular components mainly comprised of collagen.

The invention relates to a Kunitz domain peptide, designated DPI-14 herein, for inhibiting human neutrophil elastase. The invention also relates to a method of using a DPI-14 for treating cystic fibrosis or cystic fibrosis-related disease or disorder.

The present invention relates to formulations of ingredients that are useful for improving the appearance, texture and / or moisture of skin. In particular, the formulations of the present invention stimulate collagen, elastin, and lipid synthesis and / or inhibit or minimize the loss of collagen, elastin, and lipids in the skin. Additionally, the formulations of the present invention inhibit matrix metalloproteases, such as MMP-1, MMP-9, collagenase, or elastase.

Disclosed is a method for production of a bio-derived scaffold for use in regenerative medicine, which has a bio-compatibility and biodegradability and can self-organize and grow without causing calcification. The method comprises the steps of partially fixing a biological soft tissue with glutaraldehyde by cross-linking and incubating the partially fixed tissue together with an elastase.

Topical skin compositions include a complex containing components to provide a defense against the various pathway mechanisms of free radicals, reactive oxygen species, reactive nitrogen species, and other oxidizing species on the human body including the skin. The compositions may be administered by topically applying them in an amount to inhibit those mechanisms. The compositions and methods are directed to the prevention of the adverse or detrimental effects of free radicals, reactive oxygen species, reactive nitrogen species, and other oxidizing species on the human body including the skin. Thus, the compositions according to the invention improve barrier function, inhibit elastase and collagenase, and / or promote synthesis of collagen and elastin.

Compounds of formula (I):are useful as inhibitors of human neutrophil elastase.

The invention discloses a bacillus strain, which is renamed as Bacillus licheniformisú¼with its preservation strain name: Bacillus licheniformis ZJUEL31410ú¼ preservation unit: Chinese microbe cultrue preservation management committee common microbe center, preservation date: 2005-6-23, preservation number: CGMCC 1397. Said bacillus strain is used to produce elastase, whichi is used for the rejuvenation of animal meat, or the hydrolysis of silkworm chrysalis or colubilized silk.

The invention discloses an animal skin compound enzyme depilatory and the application of the depilatory. The depilatory comprises compound unhairing enzyme and additive, wherein components of the compound unhairing enzyme comprise neutral protease or alkaline protease 5-20 parts by weight, elastase 0.1-10 parts by weight and lipase 0.5-15 parts by weight. The compound enzyme depilatory which is provided by the invention can be suitable for unhairing with piled enzyme unhairing methods, piled enzyme coating unhairing methods and barrate inside bath unhairing methods in the manufacturing process of various common animal skins and leathers for various applications. The compound enzyme depilatory which is provided by the invention solves the technical problems in an existing technique that enzyme depilatory has large enzyme consumption, long unhairing time and large collagen loss, grain tightness of leathers is easily broken, the leathers are hollow and loosened, hairs can not be completely removed and the like. The pollution of sulphide is eliminated radically, and simultaneously the use value of the hairs is also increased.

The present invention relates to the Synthesis of Triterpenoid peptides and mechanism of action for Anti ageing and skin care. The present invention is directed towards anti-aging skin care compositions comprising peptides which are made by linking herbal actives to a pentapeptide for enhanced anti ageing activity by regenerating the dermal matrix. In detail, the present invention relates to the synthesis of Triterpenoid peptides, providing an enhanced and synergistic activity for reducing the consequences of ageing such as appearance of fine expression lines and wrinkles on the skin by cosmetic modes of application. The Triterpenoid peptides of the present invention with its novel dual action mode can be used for skin ageing & collagen insufficiency. Its Triterpenoid group acts by preventing oxidation and excess activity of serine proteases like elastase and collagenase that result in wrinkling of skin. With added peptides which boost the collagen and other matrix protein, Triterpenoid peptides provide a complete protection against pre mature ageing and functions as a best anti ageing ingredient.

A method is described for generating blended nucleic acid ligands containing non-nucleic acid functional units. Specifically, a SELEX identified RNA ligand to the integrin gpIIbIIIa is conjugated to the peptide Gly-Arg-Gly-Asp-Thr-Pro (SEQ ID NO:1). This blended RNA ligand inhibits the biological activity of gpIIbIIIa with high specificity. Also described is a single-stranded DNA ligand to elastase coupled to N-methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl ketone (SEQ ID NO:2). This elastase blended nucleic acid ligand inhibits the biological activity of elastase.

The invention provides compounds of formula wherein R1, R3, R4, R5, R6, R14, X, W and Z are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.

Systems, methods, and apparatuses for modulating proteases including matrix metalloproteinase (MMP), elastase, and bacterial protease in a negative pressure therapy system are described. A mesh having a sacrificial substrate is included. The sacrificial substrate includes a plurality of collagen fibers reinforced with a supporting material and intersecting with each other to form a network of collagen fibers having a plurality openings. The openings of the plurality of openings have an average area between about 0.5 mm2 and about 20 mm2 to permit the flow of negative pressure through the mesh. The sacrificial substrate can also include oxidized regenerated cellulose.

The present invention relates to a composition containing peptide of SEQ ID No. 1 linked to oleanolic acid and a method of treating skin aging. The composition effectively reduces signs of ageing due to oxidation, collagen insufficiency and excess activity of serine proteases like elastase and collagenase that result in wrinkling of skin, fine expression lines, reduced skin thickness, hyperpigmentation, under eye dark circles, and premature ageing.

The invention relates to a novel function and application of seville orange flower extract. Particularly, hesperidin, neohesperidin and other flavonoid substances in the seville orange flower extract are capable of promoting cell proliferation and expression of mRNA of fibrocyte IV-type collagen, inhibiting activities of elastase and matrix metalloproteinase, reducing damage of ultraviolet ray to cells and reducing the level of reactive oxygen species and secretion of inflammatory factors, so that the seville orange flower extract has a function of resisting radiation and aging for skins. Therefore, the invention provides a new direction of seville orange flower extract application, namely application of the seville orange flower extract in skin protecting products.

Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for treating diseases and conditions in which HNE is implicated.

The invention relates to the use of the extracts of plants of the genus Lapsana and of the species Lapsana communis L (Asteraceae) in particular. Said extracts are preferably obtained by maceration in a hydroglycolic mixture, and are used in cosmetic or dermopharmaceutical preparations for their skin-protective and radical-resistant properties. The actions of such preparations produce anti-ageing and anti-wrinkle effects, and protect the basic constituents of the cutaneous structure from the harsh effects of oxygen free radicals while prolonging the skin's suppleness and protective function. Said compositions supply protective cellular action against the deleterious effects of free radicals and those of enzymes such as elastase and hyaluronidase.

The present invention relates to methods of treating bacterial infection in a subject, degrading bacterial virulence factors, preventing bacteria from escaping phagosomes of neutrophils, and preventing bacteria from invading host cells, by use of an elastase.

The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention.

The invention provides compounds of Formula (I), stereoisomers thereof, or pharmaceutically acceptable salts of said compounds or stereoisomers, wherein R1, R2, m, p, q, R7 and R8 are as defined below, as well as compositions comprising the same, processes for making the same, and methods of using the same to treat a variety of diseases, including, those requiring interaction with metalloproteases, and more specifically with macrophage metalloelastase (MMP-12), and for the prevention and treatment of respiratory pathologies such as chronic obstructive bronchopneumopathy (COPD), emphysema, chronic bronchitis, chronic pulmonary inflammation, asthma, cystic fibrosis, acute respiratory distress syndrome (ARDS), respiratory allergies including allergic rhinitis, and also diseases associated with the production of TNFα including severe fibrotic pulmonary disease, pulmonary sarcoidosis and silicosis. The compounds of the present invention also show inhibitory activity on metalloprotease-13 (MMP-13), making them useful for the treatment of pathologies involving this enzyme, such as cancer, osteoporosis, osteoarthritis, arthritis, rheumatoid arthritis, atherosclerosis, multiple sclerosis and cardiac insufficiency.

This application discloses methods for diagnosing and treating SUI. The treatment methods are directed to inhibiting elastolysis in affected tissues and correcting imbalances in the expression of elastase enzymes and their inhibitors.

The invention relates to a method for producing elastase preparation by utilizing liquid-state fermentation of microbes. The method is characterized in that the elastase preparation is prepared by activating baclicus lincheniformis ELAT4 (CGMCC5700) which serves as a strain of elastase production, preparing a seed solution, culturing a fermentation broth, performing ventilation fermentation on deep liquid, and preparing an elastase preparation finished product. The enzyme activity of the liquid prepared by the method is 352U / ml, and the enzyme activity of the solid enzyme preparation is 2,512u / g. The method has the advantages of improving the efficiency of elastase production, strengthening the activity of the elastase and reducing the production cost, does not have the problem of waste solid treatment in the production process, does not pollute the environment, and is suitable for large-scale production of elastase.

A composition for retarding skin aging which contains an edible herb medicine or medicines round in Taiwan, in particular a plant extract or extracts having melanin formation-unhibiting, elastase-inhibiting, hyaluronidase-inhibiting, active oxygen-eliminating and / or radical-capturing type antioxidant activities, and a medicinally acceptable base and / or additives for external dermal application. The composition is useful in promoting skin whitening effects, maintaining the tension and elasticity of the skin, facilitating skin moistening and providing the skin with anti-inflammatory and / or anti-allergic properties.